Merck & Co Inc(MRK) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 13 at 5:56 PM ET (Korea 11/14 07:56)AI-drawn chart patterns are for reference only.
Full metrics table
| Index | DJIA, S&P 500, RUI | P/E | 150.9 | EPS (ttm) | 0.98 | Insider Own | 0.1% | Shs Outstand | 2.47B | Perf Week | 0.7% |
| Market Cap | 364.26B | Forward P/E | 16.57 | EPS next Y | 221.16% | Insider Trans | -8.47% | Shs Float | 2.46B | Perf Month | 1.77% |
| Enterprise Value | 408.34B | PEG | 4.93 | EPS next Q | 1.76 | Inst Own | 82.98% | Short Float | 1.08% | Perf Quarter | 8.67% |
| Income | 2.45B | P/S | 5.42 | EPS this Y | -69.08% | Inst Trans | 0.16% | Short Ratio | 2.6 | Perf Half Y | 32.66% |
| Sales | 67.23B | P/B | 8.12 | EPS next 5Y | 3.36% | ROA | 1.87% | Short Interest | 26.60M | Perf YTD | 40.38% |
| Book/sh | 18.2 | P/C | 37.35 | EPS past 3/5Y | 8.43% 21.23% | ROE | 5.07% | 52W High | -5.84% ($156.92) | Perf Year | 59% |
| Cash/sh | 3.96 | P/FCF | 24.7 | Sales past 3/5Y | 3.55% 9.34% | ROIC | 2.59% | 52W Low | 62.55% ($90.90) | Perf 3Y | 44.2% |
| Dividend Est. | $3.4 (2.3%) | EV/EBITDA | 20.88 | EPS Y/Y TTM | -86.88% | Gross Margin | 71.41% | Volatility(W/M) | 2.12% 2.91% | Perf 5Y | 75.9% |
| Dividend TTM | 3.4 | EV/Sales | 6.07 | Sales Y/Y TTM | 5.21% | Oper. Margin | 18.42% | ATR (14) | 4.15 | Perf 10Y | 142.32% |
| Dividend Ex-Date | 2026/9/15 | Quick Ratio | 1.14 | EPS Q/Q | -11.74% | Profit Margin | 3.65% | RSI (14) | 52.54 | Recom | 1.77 |
| Dividend Gr. 3/5Y | 5.42% 5.75% | Current Ratio | 1.35 | Sales Q/Q | 5.47% | SMA20 | 0.88% ($146.47) | Beta | 0.12 | Target Price | $162.96 |
| Payout | 45.05% | Debt/Eq | 1.2 | Earnings | 2026/10/29 | SMA50 | 1.11% ($146.14) | Rel Volume | 0.62 | Prev Close | $146.95 |
| Employees | 75000 | LT Debt/Eq | 1.11 | EPS/Sales Surpr. | 19.4% 4.35% | SMA200 | 14.86% ($128.64) | Avg Volume(3M) | 10.25M | Price | $147.76 |
| IPO | 1946/6/15 | Option/Short | Yes/Yes | Trades | 45871 | Volume | 6,328,349 | Change | 0.55% |
💊 This major U.S. pharmaceutical company develops Keytruda, an immuno-oncology treatment, along with vaccines and animal health medicines. Founded in the United States in 1891, it is a long-established pharmaceutical leader headquartered in the U.S. and holds leading positions globally in oncology, vaccines, and animal health.
Over the past 1 year, on the higher side
6% below its 1-year high.
Traded less than usual. That is 62% of its average volume.
MRK earns at a steady pace
Of every $100 in sales, $18.42 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -69.1% this year.
Tap to view numbers
However, it looks expensive
Counting its debt, for $100 of yearly operating cash you would pay $2,088. Peers typically go for $1,499. Compared with its own 5-year average, it is 635% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 5 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +75.9%. The S&P 500 did +61% over the same period.
Tap to view numbers
The dividend is on the small side
Pays 2.30% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 83.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #4 of 21 in the industry
Based on market cap of $364B.
ABBV#3 Abbvie Inc $521B PER 50.8 
MRK#4 Merck & Co Inc $364B PER 150.9 
NVS#5 Novartis AG ADR $294B PER 30.6 
AZN#6 Astrazeneca plc $286B PER 26.1 
AMGN#7 AMGEN Inc $252B PER 27.0 
Earnings Analysis · 8/4 Merck ($MRK) Q2 2026 Earnings Analysis — Revenue and Adjusted EPS Both Beat; Full-Year Revenue Guidance Raised Investing Guides · 4/11 The Complete 2026 Guide to U.S. Dividend Aristocrats Investing Guides · 4/1 US Stock Taxes Complete Guide 2026 — Calculation Methods and Tax-Saving Strategies for Beginners See all posts on this stock FAQ
What kind of company is MRK?
MRK belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of MRK?
The market cap of MRK is approximately $364.3B, ranking 34 within its sector.
Does MRK pay dividends?
MRK has a dividend yield of approximately 2.30%, with an annual dividend of $3.40.
What is the P/E ratio of MRK?
MRK has a P/E ratio of approximately 150.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for MRK?
MRK has recorded a 52-week high of $156.92 and a low of $90.90.
